JPS62255433A - Composition for normalizing concentration of neutral fat in blood - Google Patents
Composition for normalizing concentration of neutral fat in bloodInfo
- Publication number
- JPS62255433A JPS62255433A JP61098182A JP9818286A JPS62255433A JP S62255433 A JPS62255433 A JP S62255433A JP 61098182 A JP61098182 A JP 61098182A JP 9818286 A JP9818286 A JP 9818286A JP S62255433 A JPS62255433 A JP S62255433A
- Authority
- JP
- Japan
- Prior art keywords
- blood
- ginkgo
- concentration
- extract
- leaves
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008280 blood Substances 0.000 title claims abstract description 37
- 210000004369 blood Anatomy 0.000 title claims abstract description 37
- 230000007935 neutral effect Effects 0.000 title claims abstract description 24
- 239000000203 mixture Substances 0.000 title claims abstract description 22
- 239000004480 active ingredient Substances 0.000 claims abstract description 13
- 239000009429 Ginkgo biloba extract Substances 0.000 claims description 17
- 239000003925 fat Substances 0.000 abstract description 27
- 241000218628 Ginkgo Species 0.000 abstract description 23
- 235000011201 Ginkgo Nutrition 0.000 abstract description 23
- 235000008100 Ginkgo biloba Nutrition 0.000 abstract description 23
- 239000000284 extract Substances 0.000 abstract description 20
- 239000003960 organic solvent Substances 0.000 abstract description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 13
- 238000000605 extraction Methods 0.000 abstract description 10
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 abstract description 4
- 229930003935 flavonoid Natural products 0.000 abstract description 3
- 150000002215 flavonoids Chemical class 0.000 abstract description 3
- 235000017173 flavonoids Nutrition 0.000 abstract description 3
- 231100000957 no side effect Toxicity 0.000 abstract description 3
- 239000002904 solvent Substances 0.000 abstract description 3
- 230000035622 drinking Effects 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 210000000056 organ Anatomy 0.000 abstract 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 7
- 230000036772 blood pressure Effects 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- -1 aliphatic alcohols Chemical class 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- XMOCLSLCDHWDHP-SWLSCSKDSA-N (+)-Epigallocatechin Natural products C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-SWLSCSKDSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 241000272201 Columbiformes Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 241000218206 Ranunculus Species 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000001627 cerebral artery Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005686 eating Nutrition 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 238000004383 yellowing Methods 0.000 description 1
Abstract
Description
【発明の詳細な説明】
発明の技術分野
本発明は、血中の中性脂肪濃度の正常化に有効ないちょ
う葉エキスを含む組成物に関する。DETAILED DESCRIPTION OF THE INVENTION TECHNICAL FIELD OF THE INVENTION The present invention relates to a composition containing a butterfly leaf extract that is effective in normalizing the neutral fat concentration in the blood.
発明の技術的前日ならびにその問題点
いちょうは広く日本国内に存在しているが、このいちょ
うの緑の状態に必る葉（以下いちょう葉と略記すること
がめる）には、種々の有効成分が含有されていることか
知られている。たとえば特公昭４６−２８０９１号公報
には、いちょう葉中に脂肪族アルコール類、ケトン類、
キンクボライド類、タラボッイド類が含まれており、フ
ラボノイド類としてはガロカテキン、ガロエピカテキン
、プロデルフエニシン、フラボングルコシド、ビフラボ
ンなどが含有されていると報告されている。Technical Prelude to the Invention and Problems Ginkgo is widely available in Japan, but the leaves necessary for its green state (hereinafter abbreviated as ginkgo leaves) contain various active ingredients. It is known what has been done. For example, Japanese Patent Publication No. 46-28091 states that ginkgo leaves contain aliphatic alcohols, ketones,
It is reported that it contains kinkbolides and thalaboids, and flavonoids such as gallocatechin, galloepicatechin, proderphenisin, flavone glucoside, and biflavon.
そして同公報には、いちょう葉からこれらの有効成分を
抽出して得られるいちょう葉エギス組成物が将に老人に
おける末梢および大脳動脈の血流障害の治療に効果かお
ると記載されている。The same publication states that a ginkgo leaf Aegis composition obtained by extracting these active ingredients from ginkgo leaves will be effective in the treatment of blood flow disorders in peripheral and cerebral arteries in the elderly.
また特開昭６０−１０９５２２号公報には、上記のよう
ないらよう葉エギス組成物が神経障害、特に脳疾患など
に対して優れた効果を有することが記載されている。Furthermore, JP-A-60-109522 describes that the above-mentioned composition of Iris spp. has an excellent effect on neurological disorders, especially brain diseases.
ところで現代の日本はと食品が溢れている時代はなく、
若者の体位は飛躍的に向上している。ところが反面過食
による肥満に悩む人々か多く出現するようになっている
。肥満は、心臓に負担をかけるだけでなく、高血圧症、
動脈硬化症、心Ｗｉ病、糖尿病などの成人病を誘発づる
。このような肥満は、一般に、脂肪、糖質の摂りすぎお
るいはアルコール飲料の摂ゆすぎが原因でおるとされて
いる。By the way, there was no time in modern Japan when there was an abundance of pigeon food.
The physical condition of young people has improved dramatically. However, on the other hand, more and more people are suffering from obesity due to overeating. Obesity not only puts a strain on the heart, but also causes hypertension,
It induces adult diseases such as arteriosclerosis, heart disease, and diabetes. Such obesity is generally thought to be caused by eating too much fat and sugar, or drinking too much alcoholic beverages.
このうち脂肪の摂り過ぎによって血中の中性脂肪濃度が
高くなると、循１；器系の障害が生ずるため特に好まし
くない。Among these, it is particularly undesirable if the concentration of neutral fats in the blood increases due to excessive intake of fat, as this will cause disorders in the circulatory system.
このような血中の中性脂肪濃度の上昇は、食事面でこれ
らの中性脂肪を多く含む食品を摂取することを控えるこ
とが最も望ましいが、もし特に中［生脂肪を多く含む食
品を控えることなく血中の中性脂肪濃度を低下させるこ
とができるならば、非常に望ましいことであろうと考え
られる。In order to prevent such an increase in blood triglyceride concentration, it is best to refrain from consuming foods containing a large amount of these triglycerides, but if It would be highly desirable if it were possible to lower the neutral fat concentration in the blood without causing any damage.
発明の目的
本発明は、血中の中性脂肪濃度の正常化に有効であると
ともに、長期間にわたって飲み続けても何らの副作用あ
るいは害のないような天然の組成物を提供することを目
的としている。Purpose of the Invention The purpose of the present invention is to provide a natural composition that is effective in normalizing the neutral fat concentration in the blood and that does not cause any side effects or harm even if taken for a long period of time. There is.
発明の概要
本発明に係る血中の中性脂肪濃度正常化用組成物は、い
ちょう葉エキスを有効成分として含むことを特徴として
いる。Summary of the Invention The composition for normalizing blood neutral fat concentration according to the present invention is characterized by containing ginkgo leaf extract as an active ingredient.
本発明に係る血中の中性脂肪濃度正常化用組成物は、緑
の状態にあるいちょう葉から得られるいらよう葉エキス
を有効成分として含んでおり、この組成物を飲み続ける
と血中の中性脂肪濃度が徐々に正常化される。しかも本
発明に係る血中の中性脂肪濃度正常化用組成物は、天然
の植物葉から抽出したものであるので長期間にわたって
飲み続けても何らの０１作用も認められない。The composition for normalizing blood triglyceride concentration according to the present invention contains as an active ingredient Irayo leaf extract obtained from green ginkgo leaves, and if you continue to drink this composition, the blood concentration will increase. Triglyceride concentration gradually normalizes. Moreover, since the composition for normalizing blood neutral fat concentration according to the present invention is extracted from natural plant leaves, no 01 effect is observed even if the composition is taken continuously for a long period of time.
発明の詳細な説明
以下本発明に係る血中の中性脂肪濃度正常化用組成物に
ついて具体的に説明する。DETAILED DESCRIPTION OF THE INVENTION The composition for normalizing blood neutral fat concentration according to the present invention will be specifically described below.
本発明に係る血中の中性脂肪濃度正常化用組成物は、い
ちょう葉エキスを有効成分として含／νでおり、まずこ
のいちょう葉エキスの製造方法について説明する。The composition for normalizing blood neutral fat concentration according to the present invention contains ginkgo leaf extract as an active ingredient. First, a method for producing this ginkgo leaf extract will be explained.
いちょう葉エキスを製造するに際して用いられるいちょ
う葉は、緑の状態におるものが用いられ、黄変した状態
にあるものは用いられない。なぜなら黄変したいちょう
葉には、有効成分が必まり含まれていないからである。Ginkgo leaves used in the production of ginkgo leaf extract are those in a green state, and those in a yellowed state are not used. This is because yellowing ginkgo leaves do not necessarily contain active ingredients.
またいちょう葉は、予じめ乾燥されて砕かれた状態とし
て、以下に）ホベる抽出工程に付されることが好ましい
。Furthermore, it is preferable that the ginkgo leaves be dried and crushed in advance and subjected to the extraction step (described below).
このようないちょう葉を、約４０〜１００’Ｃ。Heat these kinds of buttercup leaves at about 40 to 100'C.
好ましくは６０〜８０℃の温度において、水と混和しう
る有機溶媒と水との混合物で抽出処理する。Preferably, the extraction treatment is carried out at a temperature of 60 to 80°C with a mixture of water and a water-miscible organic solvent.
この際抽出時間は、１〜１０時間好ましくは３〜７時間
程度であり、抽出圧力としては常圧あるいは加圧条件が
採用される。抽出操作の終了後、圧搾型理などにより、
抽出液をいちょう葉から分離する。At this time, the extraction time is about 1 to 10 hours, preferably about 3 to 7 hours, and the extraction pressure is normal pressure or pressurized conditions. After the extraction operation is completed, the
Separate the extract from the ginkgo leaves.
水と混和しうる有機溶媒としては、具体的には、アセト
ン、メチルエチルケトン、ジエチルケトンなどのケトン
類、おるいはメタノール、エタノール、ｎ−プロパツー
ル、イソプロパツール、ブタノールなどの低級アルコー
ル類などが用いられる。Examples of organic solvents that are miscible with water include ketones such as acetone, methyl ethyl ketone, and diethyl ketone, and lower alcohols such as methanol, ethanol, n-propanol, isopropanol, and butanol. used.
このような水と混和しつる有機溶媒は、水と混合されて
用いられるが、この有機溶媒は混合物中で５０〜８０重
間％の呈で用いられる。Such water-miscible organic solvents are used by being mixed with water, and the organic solvents are used in the mixture in an amount of 50 to 80% by weight.
次に、このようにして得られた含水有機溶媒抽出液に、
水と実質的に混和しない有機溶媒を加えて、約１５〜５
０’Ｃの温度において抽出操作を行なう。この際用いら
れる水と実質的に混和しない有機溶媒としては、クロロ
ホルム、四塩化炭素、メチレンジクロライドなどの脂溶
性溶媒が用いられる。Next, in the thus obtained water-containing organic solvent extract,
Adding an organic solvent that is substantially immiscible with water, approximately 15 to 5
The extraction operation is carried out at a temperature of 0'C. The organic solvent used in this case that is substantially immiscible with water includes fat-soluble solvents such as chloroform, carbon tetrachloride, and methylene dichloride.
上記のような抽出操作が加えられた含水有機溶媒抽出液
から、有機溶媒を減圧蒸留などによって除去すると、本
発明に係るいちょう葉エキスが得られる。もし必要であ
れば、このいちょう菓エキスを減圧下で乾燥させること
によって粉末状のいちょう葉エキスとすることもできる
。The ginkgo leaf extract according to the present invention can be obtained by removing the organic solvent from the water-containing organic solvent extract subjected to the above-described extraction operation by vacuum distillation or the like. If necessary, this Ginkgo confectionery extract can be dried under reduced pressure to form a powdered Ginkgo leaf extract.
またもし必要であれば、緑の状態におるいちょう葉を約
４０〜１００℃の温度にて水と混和しうる含水有機溶媒
で抽出し、得られた抽出液を約１５〜５０’Ｃにおいて
水と混和しない脂溶性有機溶媒で抽出した後、含水有機
溶媒抽出液に硫酸アンモニウムを加え、沸点約６０〜１
００’Ｃであって水に対しである程度の溶解性を有する
有機溶媒で抽出し、この抽出液を濃縮後、残留物を低級
アルコールで抽出し、抽出液から溶媒を除去することに
よって、いちょう葉エキスを調製してもよい。If necessary, the ginkgo leaves in the green state are extracted with a water-containing organic solvent miscible with water at a temperature of about 40 to 100'C, and the resulting extract is heated to about 15 to 50'C with a water-containing organic solvent. After extraction with a fat-soluble organic solvent that is immiscible with
Ginkgo leaves are extracted with an organic solvent that has a certain degree of solubility in water at 00'C, and after concentrating this extract, the residue is extracted with a lower alcohol and the solvent is removed from the extract. Extracts may also be prepared.
このようにすると、さらに精製されたいちょう菓エキス
とすることができる。In this way, a further purified ginkgo extract can be obtained.
このようにして得られるいちょう葉エキス中には、いら
よう葉に含まれるフラボノイドｍｓ−始めとして種々の
有効成分が含まれているが、脂溶性物質は除去されてい
る。The ginkgo leaf extract thus obtained contains various active ingredients including flavonoid ms contained in the ginkgo leaf, but fat-soluble substances have been removed.
このようにして得られたいちょう葉エキスは、たとえば
カプセル化されたり、錠剤化または顆粒化されたり、あ
るいはそのままの状態で、使用に供される。The ginkgo leaf extract thus obtained can be used, for example, in the form of capsules, tablets, granules, or as it is.
また必要に応じては、いちょう葉エキス中に、ビタミン
Ｅ、ビタミンＣ，などのビタミン類、おるいはベニバナ
油などの食用油を添加して用いることもできる。Further, if necessary, vitamins such as vitamin E and vitamin C, or edible oil such as safflower oil may be added to the ginkgo leaf extract.
本発明に係る血中の中性脂肪濃度正常化用組成物は、緑
の状態にあるいちょう葉から（ｑられるいちょう葉エキ
スを有効成分として含んでおり、この組成物を飲み続け
ると血中の中性脂肪濃度が徐々に正常化される。しかも
本発明に係る血中の中性脂肪濃度正常化用組成物は、天
然の植物葉から抽出したものであるので長期間にわたっ
て飲み続けても何らの副作用も認められない。The composition for normalizing blood neutral fat concentration according to the present invention contains ginkgo leaf extract extracted from green ginkgo leaves as an active ingredient, and if you continue to drink this composition, the blood neutral fat concentration will increase. Neutral fat concentration is gradually normalized.Moreover, since the composition for normalizing blood neutral fat concentration according to the present invention is extracted from natural plant leaves, there is no problem even if you continue to drink it for a long period of time. No side effects were observed.
以下本発明で用いられるいちょう葉エキスの製造方法に
ついて具体的に説明ブーる。The method for producing ginkgo leaf extract used in the present invention will be explained in detail below.
乾燥し粗く砕いたいちょう緑葉１００１（ｆｆを抽出機
に入れ、６０％アセトン水溶液５０ＯＮを用いて約５５
°Ｃで約５時間抽出処理し、その混合物を冷却した後、
抽出液をいちょう葉から分離した。Put dried and coarsely crushed Ginkgo green leaves 1001 (ff) into an extractor and extract about 55
After extraction treatment for about 5 hours at °C and cooling of the mixture,
The extract was separated from the ginkgo leaves.
得られた水性抽出液を、四塩化炭素６０ｆＪを用いて攪
拌しながら２回抽出し、四塩化炭素層を分離した。水性
アセトン層を減圧下で蒸留してアセ１〜ンを留去し、吸
湿性残漬を減圧下約５０°○で乾燥して、゛勢末状とし
た。The resulting aqueous extract was extracted twice with 60 fJ of carbon tetrachloride while stirring, and the carbon tetrachloride layer was separated. The aqueous acetone layer was distilled under reduced pressure to remove the acetone, and the hygroscopic residue was dried under reduced pressure at about 50° to give a powder.
この０末状物中には、フラボイドが含有されていること
が、フラボイド試薬でおるジフェニル回正β−アミノエ
チルエステルによる発色反応で確かめられた。The presence of flavoids in this zero powder was confirmed by a coloring reaction using diphenyl reconstituted β-aminoethyl ester as a flavoid reagent.
次に上記のようにして得られた粉末状いちょう葉エキス
を有効成分して含む水性組成物を臨床試験に用いた結果
について説明する。なおこの臨床試験は、北海道におる
原子弘漢療法院および北嵩医院において行なわれた。Next, the results of using an aqueous composition containing the powdered ginkgo leaf extract obtained as described above as an active ingredient in a clinical test will be explained. This clinical trial was conducted at Atomic Kokan Therapy Clinic and Kitataka Clinic in Hokkaido.
試験例１
初診時の血圧が１９０〜１１０でおり、血中の中性脂肪
濃度値が１３９でおる高血圧病の５９才の男性に、いち
ょう葉エキスを毎日１５０ｍＥづつ与え続けて３０日後
に再度血中の中性脂肪濃度を検査したところ、血中の中
性脂肪濃度値は９４にまで低下し、正常値の範囲となっ
た。Test Example 1 A 59-year-old man with hypertension had a blood pressure of 190 to 110 at the time of his first visit and a blood triglyceride concentration of 139. Ginkgo leaf extract was given at a dose of 150 mE every day, and the blood pressure was repeated 30 days later. When the neutral fat concentration in the blood was examined, the neutral fat concentration in the blood decreased to 94, which was within the normal range.
なお正常な人の場合には、血中の中性脂肪濃度値は６０
〜１２０桿度でおる。In addition, in the case of a normal person, the neutral fat concentration value in the blood is 60.
~120 degrees.
試論例２
初診時の血圧が１２０〜６５であり、血中の中性脂肪濃
度値が１７１でおる６２才の女性に、いちょう葉エキス
を毎日１５０ηづつ与え続けて３５日後に再度血中の中
性脂肪濃度を検査したところ、血中の中性脂肪）農度値
は７６にまで低下し、正常値の範囲となった。Essay Example 2 A 62-year-old woman whose blood pressure at the time of her first visit was 120 to 65 and whose blood neutral fat concentration was 171 was given ginkgo leaf extract at a dose of 150 η every day, and 35 days later, the blood concentration was again increased. When the sex fat concentration was tested, the neutral fat concentration in the blood decreased to 76, which was within the normal range.
試験例３
初診時の血中の中性脂肪濃度値が３９４である５６オの
男性に、いちょう菓エキスを毎日１５０ｍ「づつ与え続
けて３０日後に再度血中の中性脂肪濃度を検査したとこ
ろ、血中の中性脂肪濃度値は１４８にまで低下した。Test Example 3 A 56-year-old man whose blood triglyceride concentration was 394 at the time of his first visit was given 150 m of ginkgo extract every day, and the blood triglyceride concentration was tested again 30 days later. , blood triglyceride concentration decreased to 148.
試験例４
初診時の血中の中性脂肪濃度１直か１９４である６２才
の女性に、いもよう葉エキスを毎日１５０ｍｇづつ与え
続けて１５日２＋ａに再度血中の中性脂肪濃度を検査し
たところ、血中の中は脂肪濃度値は１０８にまで低下し
、正常値の範囲となった。Test Example 4 A 62-year-old woman whose blood triglyceride concentration was 1 or 194 at the time of her first visit was given 150 mg of potato leaf extract every day, and the blood triglyceride concentration was tested again on the 15th at 2+a. As a result, the fat concentration in the blood decreased to 108, which was within the normal range.
試験例５
初診時の血圧が１８０〜１２０であり、血中の中性脂肪
濃度値が１３０である高血圧病の５５才の男性に、いち
ょう葉エキスを毎日１５０ｍｇづつ与え続けて４２日後
に再度血中の中性脂肪濃度を検査したところ、血中の中
性脂肪濃度１直は１００にまで低下し、正常値の範囲と
なった。Test Example 5 A 55-year-old man with hypertension had a blood pressure of 180 to 120 and a blood triglyceride concentration of 130 at the time of his first visit. Ginkgo leaf extract was continued to be given at a dose of 150 mg every day, and 42 days later he was given blood pressure again. When the triglyceride concentration in the blood was examined, the triglyceride concentration in the blood decreased to 100, which was within the normal range.
試験例６
初診時の血圧が１９０〜１２５でおり、血中の中性脂肪
濃度値が１５４である高面１工病の４９才の男性に、い
ちょう葉エキスを毎日１５０ｍｙづつ与え続けて３５０
後に再度血中の中性脂肪）門度を検査したところ、Ｉｌ
’ｎ中の中性脂肪濃度値は１３２にまて低下した。Test Example 6 A 49-year-old man with Takamen 1 disease whose blood pressure at the time of his first visit was 190 to 125 and a blood neutral fat concentration of 154 was given 150 mg of ginkgo leaf extract daily.
Later, when the level of triglycerides in the blood was tested again, it was found that Il
The neutral fat concentration value in 'n decreased to 132.
Claims (1)
とする血中の中性脂肪濃度正常化用組成物。1) A composition for normalizing neutral fat concentration in blood, which contains ginkgo leaf extract as an active ingredient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61098182A JPS62255433A (en) | 1986-04-30 | 1986-04-30 | Composition for normalizing concentration of neutral fat in blood |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61098182A JPS62255433A (en) | 1986-04-30 | 1986-04-30 | Composition for normalizing concentration of neutral fat in blood |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS62255433A true JPS62255433A (en) | 1987-11-07 |
Family
ID=14212877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP61098182A Pending JPS62255433A (en) | 1986-04-30 | 1986-04-30 | Composition for normalizing concentration of neutral fat in blood |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS62255433A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995015172A1 (en) * | 1993-12-03 | 1995-06-08 | Montana Limited | Extract from the leaves of gingko biloba |
| WO1996038160A1 (en) * | 1995-06-01 | 1996-12-05 | Montana Limited | Extract from the leaves of ginkgo biloba |
| US6086883A (en) * | 1993-12-03 | 2000-07-11 | Montana Limited | Extract from the leaves of Ginkgo biloba |
| JP2004002335A (en) * | 2002-03-28 | 2004-01-08 | Ortho Corporation | Agent for ameliorating symptom of indefinite complaint, food and composition thereof |
-
1986
- 1986-04-30 JP JP61098182A patent/JPS62255433A/en active Pending
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995015172A1 (en) * | 1993-12-03 | 1995-06-08 | Montana Limited | Extract from the leaves of gingko biloba |
| US6086883A (en) * | 1993-12-03 | 2000-07-11 | Montana Limited | Extract from the leaves of Ginkgo biloba |
| CN1083717C (en) * | 1993-12-03 | 2002-05-01 | 蒙大拿有限公司 | Extract from the leaves of gingko biloba |
| WO1996038160A1 (en) * | 1995-06-01 | 1996-12-05 | Montana Limited | Extract from the leaves of ginkgo biloba |
| US5885582A (en) * | 1995-06-01 | 1999-03-23 | Montana Limited | Extract from the leaves of ginkgo biloba |
| JP2004002335A (en) * | 2002-03-28 | 2004-01-08 | Ortho Corporation | Agent for ameliorating symptom of indefinite complaint, food and composition thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2523384C2 (en) | Phytocomplex of bergamot fruit, method for preparing and using as food additive and in pharmacology | |
| JPWO2009093584A1 (en) | Preventive or ameliorating agent for plant-derived hyperuricemia | |
| EP0573682A1 (en) | Tea polyphenols as anti-hyperglycemic agents | |
| JP3968405B2 (en) | Antiallergic agent | |
| US7767236B2 (en) | Plant seed extract composition and process for producing the same | |
| JP4516282B2 (en) | Novel substance having α-glucosidase inhibitory activity and food containing the same | |
| RU2701567C1 (en) | Agent possessing hepatoprotective activity | |
| JP2003146898A (en) | Hyperlipemia-improving agent | |
| CN101146458A (en) | A method for preparing extract for the prevention and treatment of hyperlipidemia and obesity from the extract of aster spathulifolius aerial part and composition containing the same | |
| JPH09234018A (en) | Beverage and food product having preventing action on diabetic complication | |
| JPS62255433A (en) | Composition for normalizing concentration of neutral fat in blood | |
| KR101821925B1 (en) | A composition comprising the complex extract of Poncirus trifoliata and Cinnamommum cassia for treating or preventing allergy desmatitis | |
| Winifred et al. | Biochemical studies of the ameliorating effects of bitter leaf and scent leaf extracts on diabetes mellitus in humans | |
| EP3117825A1 (en) | Oral formulation comprising berberine and morus alba extract | |
| KR19990071183A (en) | Honggyeongcheon Extract with Efficacy and Prevention of Circulatory Diseases | |
| JP2003063974A (en) | Antioxidant, nitrogen monooxide-production inhibitor, antiulcer drug and food containing the drug component | |
| EP2124980A1 (en) | Composition comprising trachelospermi caulis and pyrola japonica extracts for the treatment and prevention of inflammatory diseases | |
| JP2005047839A (en) | Proanthocyanidin-containing composition | |
| KR101440781B1 (en) | Composition for Improving Liver Function Using an Extract of Wheat Bran | |
| CN107183716A (en) | A kind of liver protection is dispelled wine health-care food composition and preparation method thereof | |
| JP2004137218A (en) | Lipolysis promoter, and skin care preparation for external use and food and drink product using the same | |
| JP2005060338A (en) | Proanthocyanidin-including composition | |
| EP1495765A1 (en) | Composition for preventing arteriosclerosis | |
| JP2005350432A (en) | Prostacyclin formation promoter | |
| JP2001046019A (en) | Nutritive composition originated from citrus fruit |